Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangxi Institute of Biological Products FCF Margin %?
Jiangxi Institute of Biological ProductsHKSE:06915 +1.33%23 FCF Margin % is 8.83% as of Dec. 2025, which is 53% below its 10-year median of 18.95. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 964 Drug Manufacturers companies, Jiangxi Institute of Biological Products ranks better than 67.43% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products FCF Margin % Chart
Jiangxi Institute of Biological Products Annual Data
Trend
Dec23
Dec24
Dec25
FCF Margin %
18.95
30.54
8.83
Jiangxi Institute of Biological Products Semi-Annual Data
Dec23
Dec24
Dec25
FCF Margin %
18.95
30.54
8.83
HKSE:06915 vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Institute of Biological Products FCF Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products (HKSE:06915) has a FCF Margin % of 8.83% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jiangxi Institute of Biological Products and its competitors. This is 53% below median its historical median of 18.95. Over the past decade, Jiangxi Institute of Biological Products' FCF Margin % has ranged from 8.83 to 30.54. According to the industry distribution chart, Jiangxi Institute of Biological Products ranks #314 out of 964 companies in the Drug Manufacturers industry, placing it in the top 32.6%.
Is Jiangxi Institute of Biological Products' FCF Margin % too high?
Jiangxi Institute of Biological Products' current FCF Margin % of 8.83% is 53% below median its 10-year median of 18.95. Over the past 10 years, this metric has ranged from a low of 8.83 to a high of 30.54. The Drug Manufacturers industry median FCF Margin % is 2.74. Jiangxi Institute of Biological Products' value of 8.83% is 222.3% above this industry median. Based on the distribution chart, Jiangxi Institute of Biological Products ranks #314 out of 964 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Jiangxi Institute of Biological Products ranks #314 out of 964 companies for FCF Margin %. This puts Jiangxi Institute of Biological Products in the upper half of its industry. The industry median FCF Margin % is 2.74. Jiangxi Institute of Biological Products' value of 8.83% is 222.3% above this benchmark. Historically, Jiangxi Institute of Biological Products' own FCF Margin % has ranged from 8.83 to 30.54 over the past decade. While the company's 10-year median is 18.95 vs. the industry median of 2.74, Jiangxi Institute of Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.74, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Institute of Biological Products's current FCF Margin % of 8.83% is 222.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jiangxi Institute of Biological Products and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Institute of Biological Products's current FCF Margin % is 8.83%, which is 53% below median its own 10-year median of 18.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current FCF Margin % of 8.83%. The current FCF Margin % is 8.83%, which is 53% below median its 10-year median of 18.95 and 222.3% above the Drug Manufacturers industry median of 2.74. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current FCF Margin % is 8.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score
Get the complete analysis for HKSE:06915
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06915 has been successfully added to your 
